bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
123 hedge funds and large institutions have $845M invested in bluebird bio in 2014 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 54 increasing their positions, 20 reducing their positions, and 20 closing their positions.
202% more call options, than puts
Call options by funds: $19M | Put options by funds: $6.3M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
170% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 20
95% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 20
18% more funds holding
Funds holding: 104 → 123 (+19)
14% more capital invested
Capital invested by funds: $742M → $845M (+$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.8M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$17.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$17.5M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$13.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
-$42.8M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$25.3M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$6.9M |
| 4 |
PC
PointState Capital
New York
|
-$5.17M |
| 5 |
Goldman Sachs
New York
|
-$2.23M |
BLUE Hedge Fund Activity: Q3 2014 in Review
123 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2014, worth a combined $845M — up 14% from $742M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new BLUE positions and 20 closed out — a net gain of 19 holders — while 54 added to existing stakes and 20 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $38M. The largest seller was Third Rock Ventures, cutting an estimated $42.8M.
- 123 institutional investors held bluebird bio (BLUE) as of Q3 2014, up from 104 in Q2 2014.
- Funds reported $845M of bluebird bio stock for Q3 2014, up 14% quarter-over-quarter.
- 39 funds opened new bluebird bio positions in Q3 2014 and 20 closed out, a net change of +19 holders.
- The largest bluebird bio buyer in Q3 2014 was T. Rowe Price Associates, an estimated $38M added.
- The largest bluebird bio seller in Q3 2014 was Third Rock Ventures, an estimated $42.8M sold.
Based on aggregated 13F filings for Q3 2014.